Conditional marketing authorisations, exceptional circumstances MAs, scientific advice

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance for pharmaceutical companies regarding Conditional Marketing Authorisations (CMA) and Authorisations under Exceptional Circumstances. Operating under the Human Medicines Regulations 2012 and the Windsor Framework (effective January 2025), this guidance outlines pathways for medicinal products addressing unmet medical needs where comprehensive clinical data is currently unavailable. While this is general regulatory guidance rather than a specific company inspection, it establishes strict requirements for all applicants. For a CMA, companies must demonstrate that a medicine’s immediate benefit outweighs the risks of incomplete data, specifically for life-threatening or seriously debilitating conditions. Required actions for companies include submitting a full marketing authorization dossier accompanied by a justification for the conditional route and a timeline for forthcoming clinical data. Once granted, companies must fulfill specific post-approval obligations, such as completing ongoing trials, and renew the authorisation annually. In cases of 'Exceptional Circumstances'—where data collection is impossible due to the rarity of a condition—companies are required to consult the MHRA before submission. The MHRA also provides a scientific advice service to assist developers in navigating these requirements, with fee exemptions available for small and medium-sized enterprises.